A Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Initial Efficacy of JS212 in Subjects With Advanced Malignant Solid Tumour

NCT06888830 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

374

Enrollment

OTHER

Sponsor class

Conditions

Advanced Malignant Solid Tumours

Interventions

DRUG: JS212 for Injection

Sponsor

Shanghai Junshi Bioscience Co., Ltd.